Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1
by Zacks Equity Research
Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.
Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up
by Zacks Equity Research
Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
4 Warren Buffett Stocks to Buy in Q2 Earnings
by Tirthankar Chakraborty
We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.
Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TEVA) Outperforming Other Medical Stocks This Year?
TEVA or AKRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TEVA vs. AKRX: Which Stock Is the Better Value Option?
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Teva to Discontinue a Fremanezumab Study on Cluster Headache
by Zacks Equity Research
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
by Zacks Equity Research
Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
by Zacks Equity Research
AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate
by Zacks Equity Research
Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why
by Zacks Equity Research
Teva's (TEVA) shares gain 17% in 2018 so far after declining sharply in 2017.
FDA Confirms September Action Date for Teva's Migraine Drug
by Zacks Equity Research
Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.
Should You Hold Momenta (MNTA) Stock in Your Portfolio?
by Zacks Equity Research
Momenta (MNTA) is conducting a strategic review of its ongoing operations as revenues from Glatopa continue to decline.
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
by Zacks Equity Research
Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.
Company News For May 17, 2018
by Zacks Equity Research
Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B
Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
by Zacks Equity Research
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
by Zacks Equity Research
Teva's (TEVA) shares gain 5% after Warren Buffett's Berkshire Hathaway reveals an increased stake in the company.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.
BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.
Mylan (MYL) Q1 Earnings Lag on Weak North America Sales
by Ekta Bagri
Mylan's first-quarter results were dismal with both earnings and sales missing expectations as challenges in North America persist.
Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline
by Zacks Equity Research
Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1.
Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.